Ultrasound activated
magnetosome-enhanced thermal treatment of prostate tumors
AlphaOnco is pioneering a novel, non-invasive prostate cancer therapy using magnetosomes—naturally derived magnetic nanoparticles—combined with focused low-intensity ultrasound.
This unique approach enables localized tumor destruction at moderate temperatures without the need for general anesthesia, surgical procedures, or radiotherapy. The treatment is designed for outpatient use, significantly reducing cost, patient risk, and recovery time. With 13 global patent families, validated efficacy in multiple tumor models, and preclinical evidence showing full tumor disappearance with no regrowth, AlphaOnco is positioned to transform focal therapy in prostate cancer.
Treatment aims at
Simplicity:
It can be carried out easily, under simple consultation, alone or in complement to surgery/radiotherapy, no general anesthesia, no operation theatre, minimal use of hospital infrastructure.
Minimal use of hospital infrastructure:
It can be performed outside the operation theatre.
Studies on our treatment
Demonstrate efficacy and safety pre-clinically:
- It leads to full tumor disappearance with no tumor regrowth and minimal side effects in mice bearing prostate tumor.
- It has demonstrated efficacy on several tumor models (breast, glioblastoma, prostate in mice; spontaneous sarcoma in dog) using various heating sources (magnetic field, laser, ultrasound).*
Rely on solid scientific foundation:
It gave birth to:
- 40+ peer-reviewed publications,
- 13 patent families.
*According to our publications
Prostate cancer: a major public health challenge
Prostate cancer affects over 1.5 million diagnosed men worldwide, yet current treatments often involve surgery, radiation, often leading to long-term side effects such as impotence or incontinence.
Current treatments and their limitations
- Side effects;
- Operation theatre required;
- General anesthesia needed;
- Prostate malfunction/removal;
- Need of expensive, big, dedicated equipment (for radiotherapy or robotic surgery);
- Expensive;
- Lack of full efficacy;
- Complex to implement.
Our innovation
Breakthrough in cancer therapy
AlphaOnco is pioneering a novel focal therapy for intermediate to advanced prostate cancer*, leveraging mild ultrasound-induced hyperthermia in combination with natural iron oxide nanoparticles, known as magnetosomes.
* Prostate tumors eligible for focal therapy
Suspension of Magnetosomes
- Pure, non-toxic, biocompatible, biocompatible, stable nano-minerals*
- Produced naturally by non-pathogenic bacteria*
- Organic material originating from bacteria de-activated, removed*
- Chain arrangement provides good anti-tumor activity under moderate heating conditions*
Low Intensity Ultrasound Heating Module
- Moderate heating*
- Low intensity*
- Whole tumor coverage*
- Designed to be compatible with commercial ultrasound imaging probe
Our Science
Designed for patients.
Trusted by science.
Our treatment is based on naturally derived iron oxide nanoparticles (magnetosomes), manufactured in-house and injected directly into the tumor. When excited by ultrasound, the tumor generates gentle heat with an anti-tumor activity enhanced by the presence of magnetosomes, leading to full cancer cell eradication, with a high safety profile.
AlphaOnco is the only company worldwide with the capability to produce both therapeutic-grade magnetosomes & the ultrasound-based heating probe, and to master their associated methods of treatments, which are protected world wide by 13 patent families, and have given birth to 40+ publications.
The therapy is designed to be user-friendly and cost-efficient, supporting broad and scalable clinical implementation.
About us
Advancing Cancer Treatment Through Innovation
AlphaOnco (formerly Nanobacterie) is the result of over 15 years of pioneering research led by Dr. Edouard Alphandéry in nanomedicine. Our team has been formed to gather scientists, clinicians, and entrepreneurs with fully interdisciplinary & complementary skills.
Invest in AlphaOnco
Our journey to be shared with others
AlphaOnco has been supported by public and private funds, the latter originating from family & friends and an investment company: EP Equity Investment.
Further funds are needed to ensure industrial Scalability, clinical trial realization, production up-scaling,
Investment is attractive due to the advantages of the developed treatment, capital managed efficiently, scientific excellence.
